Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

pond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), advanced age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. Increasing incidence, higher treatment failures and recurrence with current therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials.

About FidaxomicinFidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of C. difficile. The narrow-spectrum profile of fidaxomicin may eradicate C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics to treat CDI, metronidazole and vancomycin, disrupt the flora. Fidaxomicin may facilitate the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). Optimer has completed two Phase 3 trials of fidaxomicin for the treatment of CDI, demonstrating that fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Optimer has also successf
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... N.C. , May 20, 2013 ... focused on developing differentiated antibiotics to meet critical ... today announced that it presented data at the ... Philadelphia demonstrating the antibacterial ... in Cempra,s prior Phase 2 clinical trial in ...
(Date:5/20/2013)... FL (PRWEB) May 20, 2013 Researchers from ... in the connection between lower back pain, and the acne ... P.acnes in the system the bacteria seek out oxygen deprived ... incurred in the spinal column, P.acnes has the ability to ... , Fernando Perez, a spokesman for “ The best ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 In Early ... the field of biotoxin related illnesses , announced his ... country able to advance his protocol for treating Chronic ... became the third physician to achieve certification in the ... Physicians, able to practice the Shoemaker Protocol in other ...
(Date:5/17/2013)... Topricin Pain Relief and Healing Cream, ... among nationally recommended over-the-counter (OTC) health products 2012 ... News" Health in collaboration with "Pharmacy Times." ... Pharmacists Recommended designation” in the “Topical Analgesics” category, ... is the only homeopathic formula to earn that ...
Breaking Biology Technology:Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2
... Molecular Devices Limited, U.K., , ... The FlexStation scanning ... it ideal for kinetic, cell-based fluorometric assays, such as the ... Calcium (Ca 2+ ) is the most common signal transduction ...
... FOR DIVERSIFIED TARGETS, , , , , ... CELL TYPES , , HIGHER SIGNAL INTENSITY , ... COMPATIBLE WITH MORE TARGETS , , ... Calcium mobilization assays for screening GPCR targets are preferred techniques ...
... McGown, Ph.D. and Michael Su, M.S., ... Molecular Devices Corporation, 8/00 , , INTRODUCTION ... study eukaryotic gene expression. Dual geneticreporters are commonly used in ... differences in cell number, viabilityor transfection efficiency. One vector containing ...
Cached Biology Technology:Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 2Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 3Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 4Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 5Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 6Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 7Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 8Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 9FLIPR Calcium 3 Assay Kit Datasheet 2FLIPR Calcium 3 Assay Kit Datasheet 3Dual-Luciferase Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #39) 2Dual-Luciferase Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #39) 3Dual-Luciferase Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #39) 4Dual-Luciferase Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #39) 5Dual-Luciferase Quantitation in the LMax Microplate Luminometer (MaxLine Application Note #39) 6
(Date:5/20/2013)... Bristol and published online today in the Journal ... brain and inner ear developed in dinosaurs. , ... with Tom Hbner from the Niederschsische Landesmuseum in Hannover, ... dinosaurs. , The two palaeontologists studied different fossils of ... young (juvenile) individual of approximately three years of ...
(Date:5/19/2013)... and women of European descent inherit common foot disorders, ... including hammer or claw toe. Findings from the Framingham ... disorders in humansappear in Arthritis Care & Research ... the American College of Rheumatology (ACR). , Previous ... adults have foot disorders which may limit mobility and ...
(Date:5/19/2013)... Davis have engineered a strain of photosynthetic cyanobacteria to ... their findings today at the 113th General Meeting of ... we used synthetic biology approaches to probe and rewire ... for growth) cyanobacterial metabolism for the ability to grow ... on the study. He is part of Shota ...
Breaking Biology News(10 mins):Fossil brain teaser 2Blame your parents for bunion woes 2
... People who eat baked or broiled fish on a ... reducing their risk of developing mild cognitive impairment (MCI) ... at the annual meeting of the Radiological Society of ... to establish a direct relationship between fish consumption, brain ...
... It feels like bone. For the most part, it acts ... State University researchers have used a 3D printer to create ... orthopedic procedures, dental work, and to deliver medicine for treating ... for new bone to grow on and ultimately dissolves with ...
... residential soils study, one of few such U.S. studies ever ... from a study of residential soils in the city of ... U.S. urban soil studies ever conducted. The authors of ... journal Environmental Pollution , collected soils in the residential ...
Cached Biology News:Eating fish reduces risk of Alzheimer's disease 2UI engineers conduct residential soils study, one of few such US studies ever done 2UI engineers conduct residential soils study, one of few such US studies ever done 3
SDS-OutT SDS Precipitation Reagent...
... Disposable, clear, APET plastic tray. Ideal ... identify those trays used for multipurposes. Pour ... liquid. A marker or label may be ... stacking trays on rockers or shakers for ...
... disposable microfiltration devices for the fast and reliable ... l to 500 l. They can be used ... tubes. Product Features: High-flux Polyethersulphonemembrane ... hold up volume ( Fast and reproducible performance ...
... is a novel disposable spin filtration device ... bacterial lysates in plasmid purification procedures. ... disposable spin filtration device especially designed to ... plasmid purification procedures. The neutralized lysate is ...
Biology Products: